The US and Canada have healthcare, life science and medical device industries that are complex and interconnected.

On March 6, President Donald Trump instituted a 25 percent ad valorem rate of duty on goods imported from Canada under the International Emergency Economic Powers Act.[1] The tariffs will not be implemented on goods that comply with the United States-MexicoCanada Agreement until April 2.[2] In turn, Canada has announced a $155 billion tariff package on the US.[3]

Download the full Law360 article, "Mitigating Tariff Risks For Healthcare In US And Canada."



Contacts

Jeff Wurzburg
Jeff Wurzburg
Partner
Email
jeff.wurzburg@nortonrosefulbright.com
T: +1 210 270 9338
Vanessa Grant
Vanessa Grant
Senior Partner
Email
vanessa.grant@nortonrosefulbright.com
T: +1 416 216 4056

Practice areas:

Industry:

Recent publications

Publication

Tariff uncertainty and M&A deals

The current tariff environment presents merger and acquisition opportunities in some sectors and jurisdictions.

Global | May 01, 2025

Mergers and acquisitions
Generic-building-skyscraper-windows-office

Publication

Faster USPTO patent grants after payment of issue fee

Effective May 13, 2025, the USPTO’s expected timeframe between issue notification and issue date will be approximately two weeks (instead of approximately three weeks)

Canada | April 28, 2025

Intellectual property
AI inspired face with light burst on head

Publication

Prosecuting AI-related patents in China

AI technology is flourishing in China, leading to a surge in innovators seeking to protect their intellectual property.

Canada | April 24, 2025

Artificial intelligence (AI)
Site search

Subscribe and stay up to date with the latest legal news, information and events . . .

Subscribe now